Baird has adjusted its price target for CVS Health (CVS, Financial), boosting it from $51 to $71 while maintaining a Neutral rating for the shares. This change reflects a cautious outlook on the managed care and healthcare facilities sector, as the firm anticipates limited new stock buyers until certain policy issues become clearer.
The firm does not foresee companies in this sector raising their guidance in the near term. This is largely because businesses are expected to maintain a conservative stance regarding their 2025 projections. Such caution is deemed necessary due to potential challenges related to Part D and broader macroeconomic factors that could arise later in the year.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 24 analysts, the average target price for CVS Health Corp (CVS, Financial) is $72.02 with a high estimate of $85.00 and a low estimate of $48.01. The average target implies an upside of 4.07% from the current price of $69.20. More detailed estimate data can be found on the CVS Health Corp (CVS) Forecast page.
Based on the consensus recommendation from 29 brokerage firms, CVS Health Corp's (CVS, Financial) average brokerage recommendation is currently 2.2, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for CVS Health Corp (CVS, Financial) in one year is $87.74, suggesting a upside of 26.79% from the current price of $69.2. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the CVS Health Corp (CVS) Summary page.
